title: PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration.
abstract: We measured cerebral glucose utilization and fluorodopa metabolism in the brain of patients with corticobasal degeneration using position emission tomography. The clinical pictures are distinctive, comprising features referable to both cerebral cortical and basal ganglionic dysfunctions. Brain images of glucose metabolism can demonstrate specific abnormalities with a marked asymmetry in the parietal cortex (the primary motor and sensory cortex and the lateral parietal cortex), the thalamus, the caudate nucleus and the putamen of the dominantly affected hemisphere related to clinical symptoms in six patients. [18F]dopa uptake also reduced in an asymmetric pattern, both the caudate nucleus and the putamen in four patients. This unique combination study measuring both cerebral glucose utilization and fluorodopa metabolism in the nigrostriatal system can provide efficient information about the dysfunctions which are correlated with individual clinical symptoms.
authors.affiliation: Department of Neurology, Miyagi National Hospital, Sendai, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Nagasawa
authors.forename: H
authors.initials: H
authors.lastname: Tanji
authors.forename: H
authors.initials: H
authors.lastname: Nomura
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: Y
authors.initials: Y
authors.lastname: Itoyama
authors.forename: I
authors.initials: I
authors.lastname: Kimura
authors.forename: S
authors.initials: S
authors.lastname: Tuji
authors.forename: T
authors.initials: T
authors.lastname: Fujiwara
authors.forename: R
authors.initials: R
authors.lastname: Iwata
authors.forename: M
authors.initials: M
authors.lastname: Itoh
authors.forename: T
authors.initials: T
authors.lastname: Ido
mesh_terms: D000368:Aged; D001072:Apraxias / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D001284:Atrophy; D001479:Basal Ganglia / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D001480:Basal Ganglia Diseases / Q000000981:diagnostic imaging / Q000473:pathology; D001927:Brain Diseases / Q000000981:diagnostic imaging* / Q000473:pathology; D002540:Cerebral Cortex / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D002560:Cerebrovascular Circulation; D003847:Deoxyglucose / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004292:Dominance, Cerebral; D005260:Female; D019788:Fluorodeoxyglucose F18; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009410:Nerve Degeneration; D014055:Tomography, Emission-Computed
chemical_list: D019788:Fluorodeoxyglucose F18; C054651:2-fluorodopa; D004295:Dihydroxyphenylalanine; D003847:Deoxyglucose; D005947:Glucose